Skip to main content

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

In an international, multi-center trial of azacitidine in patients with either intermediate-2 or high-risk MDS, overall survival was significantly increased when compared to conventional therapy, which at the discretion of the investigator and patient, could have included intense chemotherapy, low-dose cytarabine, or best supportive care.

Azacitidine for High-risk MDS